Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - The Australian Red Cross Blood Service, Costar Pharma Laboratory Pty Ltd, Sandoz Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the importation, supply, and other activities related to therapeutic goods in Australia. This legislation was introduced to ensure that therapeutic goods available in the Australian market are safe, of high quality, and effective. The Act is overseen by the Therapeutic Goods Administration (TGA), a department within the Australian Government's Department of Health. The primary policy objective of the Act is to protect public health by regulating the life cycle of therapeutic goods, from their development and clinical trials through to their manufacture, supply, and post-market surveillance. The Act provides a framework for the regulation of therapeutic goods, ensuring they meet necessary standards and are appropriately advertised and labelled. The gazette in question pertains to the publication of the list of manufacturers granted a licence for the manufacture of therapeutic goods, ensuring compliance with the Act and maintaining public health standards.

Scope and Application

The Therapeutic Goods Act 1989 is a Commonwealth legislation administered by the Therapeutic Goods Administration, a division of the Department of Health. The Act applies to entities and individuals involved in the manufacture, importation, supply, or advertising of therapeutic goods within Australia. Therapeutic goods encompass a wide range of products including medicines, medical devices, blood and blood components, and therapeutic goods used in clinical trials. The Act imposes requirements for the registration, licencing, and quality standards of these goods to ensure they are safe and of acceptable quality. The geographic reach of the Act is national, applying uniformly across all states and territories of Australia. The Act also provides for the establishment of exclusions, exemptions, and thresholds through subordinate instruments, which can further refine the scope of application. For example, certain low-risk therapeutic goods may be subject to different or reduced regulatory requirements. This legislation is crucial for maintaining the integrity and safety of the therapeutic goods market in Australia, ensuring that only products meeting stringent safety and quality standards are available to consumers.

Key Provisions

The Therapeutic Goods Act 1989, as referenced in Section 38, mandates that the Secretary grants licences to entities for the manufacture of therapeutic goods. In this specific instance, the Secretary has granted licences to four entities: The Australian Red Cross Blood Service - An Operating Division of The Australian Red Cross Society for two locations (Section 38(1)), Costar Pharma Laboratory Pty Ltd (Section 38(1)), and Sandoz Pty Ltd (Section 38(1)). Each entity has been assigned a unique licence number, indicating the specific location and premises for which the licence is valid. Entities granted a licence under Section 38 of the Therapeutic Goods Act 1989 must comply with the requirements and conditions outlined in the Act. This includes adhering to manufacturing standards, quality control processes, and other regulatory obligations aimed at ensuring the safety and efficacy of the therapeutic goods produced. For example, The Australian Red Cross Blood Service must ensure that their blood donor centres operate within the scope of their licence and meet all quality and safety standards as specified by the Act. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in significant legal consequences. Offences under the Act can lead to both civil and criminal penalties. For instance, manufacturing therapeutic goods without a valid licence, or contravening the conditions of a licence, may result in criminal charges. The maximum penalties for such offences can include substantial fines and imprisonment, as outlined in the relevant sections of the Act. Additionally, entities may face civil actions for damages resulting from non-compliance, which can further compound the financial and reputational risks. In summary, Section 38 of the Therapeutic Goods Act 1989 provides the legal framework for the issuance of manufacturing licences for therapeutic goods. Entities granted such licences must strictly adhere to the regulatory requirements to avoid the severe civil and criminal penalties that may be imposed for non-compliance. The publication of the list of manufacturers granted licences serves as an official record and public notice of these authorisations, ensuring transparency and accountability within the therapeutic goods industry.